Replies to post #790379 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

In the oft chance it gets approved (sure raising question with this extremely loooong timeframe), UK is a small oncology market and NICE will recommend it NOT be covered because of the very high cost of DCVax-L. Not a lot of revenue potential.